Status:
SUSPENDED
Coronavirus (COVID-19) ACEi/ARB Investigation
Lead Sponsor:
National University of Ireland, Galway, Ireland
Conditions:
Hypertension
COVID-19
Eligibility:
All Genders
60+ years
Phase:
PHASE4
Brief Summary
Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because SARS-CoV-2 is known to require the angiotensi...
Eligibility Criteria
Inclusion
- Men and non-pregnant women aged 60 or over
- Known diagnosis of hypertension
- Current use of ACEi or ARB for the treatment of hypertension
- COVID-19 naïve (i.e. not known to be infected)
- English speaker
Exclusion
- Known diabetic nephropathy
- Known heart failure with reduced ejection fraction
- Resistant hypertension (defined as blood pressure that remains above goal despite concurrent use of three anti-hypertensive agents of different classes, one of which should be a diuretic, or as blood pressure that is controlled with four or more medications)
- Contraindications or allergies to CCB or Thiazide
- Unconscious patients
- Current psychiatric in-patients
- Patients in an emergency medical setting
- Inability to consent
Key Trial Info
Start Date :
April 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
2414 Patients enrolled
Trial Details
Trial ID
NCT04330300
Start Date
April 30 2020
End Date
December 1 2021
Last Update
June 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Galway
Galway, Ireland, H91 YR71